ESR1 and breast carcinoma: In clinical practice, immunohistochemical analysis of estrogen receptors (ER), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 has been conducted as alternative markers for determining breast cancer molecular subtypes [3].